(TSX: PTZ) Pethealth Inc. ("Pethealth" or "the Company") today announced its financial results for the year and quarter ended December 31, 2012.
Year-end PetPoint Report reflects growth in users and increase in live release rates for animal welfare organizations.
(TSX:PTZ) Pethealth Inc. (“Pethealth” or the “Company”) released its second annual PetPoint Report today, a comprehensive year-end report comparing same shelter aggregate data from 2012 and 2011, emphasizing key trends in animal welfare related to cats and dogs in the United States.
(TSX: PTZ) Pethealth Inc. (“Pethealth” or the “Company”) saw continued growth in its non-insurance operations in 2012, led by its microchipping operations in the United States, Canada and the United Kingdom.
(TSX: PTZ) The Board of Directors of Pethealth Inc. (“Pethealth” or the “Company”) today announced that they declared a dividend of $0.12 per series I 6% convertible preference shares (the “Convertible Preference Shares”), payable on January 24, 2013, to the holders of record at the close of business on January 21, 2013.
(TSX: PTZ) Pethealth Inc. ("Pethealth" or "the Company") today announced its financial results for the quarter and nine months ended September 30, 2012.
Company supports fight against cancer through promotion of exclusive new MiniChip for pet identification and responsible pet ownership.
(TSX:PTZ) Pethealth Inc. (“Pethealth” or the “Company”) is pleased to announce a donation of $14,500 to the American Breast Cancer Foundation (“ABCF”), its third through its ‘Recover a Pet, Uncover a Cure’ campaign. The campaign was developed to help the fight against breast cancer and to raise awareness of the MiniChip, launched in January of this year and offered exclusively in North America through the Company’s 24PetWatch brand. Through an agreement signed with the not-for-profit organization in January, a portion of the purchase price of every MiniChip sold in the United States will be donated each quarter to support ABCF programs. With this m ost recent donation for the Company’s third quarter, donations to the American Breast Cancer Foundation now total over $44,000 year to date.
Survey results illustrate post-adoption decisions regarding veterinary service and pet pharmacy purchases.
(TSX: PTZ) Pethealth Inc. (“Pethealth” or the “Company”), is pleased to announce the publication of its second aggregate survey findings of new pet adopters of a dog or cat. The Q3-2012 Adopter Survey: Veterinary Services (“Veterinary Survey”) represents the largest of its kind conducted by the Company to date, surpassing the results of its Q2 aggregate survey report. Surveys were received by nearly 246,000 adopters across the United States and over 10,000 adopters completed the survey. Survey respondents include new pet adopters of dogs and cats during the 13 month period between July 2011 and July 2012; the survey was conducted during September 2012.
(TSX:PTZ) Pethealth Inc. (“Pethealth” or the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has approved its notice of intention to make a normal course issuer bid (the “Bid”) for its outstanding common shares (the “Shares”). Pursuant to the notice, Pethealth is entitled to purchase up to 1,668,604 Shares, representing 10% of its public float of 16,686,049 Shares during the twelve month period commencing September 24, 2012, and ending September 23, 2013.
(TSX: PTZ) Pethealth Inc. ("Pethealth" or "the Company") today announced its financial results for the quarter and six months ended June 30, 2012.
(TSX: PTZ) Pethealth Inc. (“Pethealth” or the “Company”), North America’s leading provider of companion animal RFID technology operating in the United States, Canada, and the United Kingdom and the leading provider of animal management software and related database services to North American animal welfare organisations (“AWOs”) is pleased to announce it has partnered with Velcera, Inc., parent company of FidoPharm, Inc. (“FidoPharm”). This exclusive partnership provides Velcera distribution of PetArmor® flea and tick medications and other FidoPharm products to Pethealth’s extensive network of AWOs using its 24PetWatch microchip programs and nearly 1,800 AWOs licensed with the Company’s PetPoint animal management system operating across the United States. PetArmor is the first EPA-approved generic fipronil flea and tick treatment for both dogs and cats. It contains the #1 veterinarian- recommended active ingredient and in the same concentration as the leading brand competitor, providing the same veterinarian-quality flea and tick protection for approximately half the cost.